CARM Profile
Carisma Therapeutics, Inc. is a biopharmaceutical company focused on developing advanced chimeric antigen receptor (CAR) macrophage therapies for the treatment of solid tumors. The company leverages cutting-edge techniques in macrophage biology, CAR engineering, and adoptive cellular therapy to create innovative treatments designed to enhance both innate and adaptive immune responses against cancer. These therapies are tailored to target and eliminate tumor cells more effectively while minimizing damage to surrounding healthy tissue.
Carisma’s proprietary technology utilizes engineered macrophages, which are key components of the immune system capable of recognizing and attacking cancer cells. By incorporating CAR technology, Carisma aims to improve the specificity and efficacy of macrophage-based therapies. This approach represents a significant advancement in the field of cellular immunotherapy, potentially offering new treatment options for patients with challenging and resistant solid tumors.
The company has established a strategic collaboration with Moderna Inc., aimed at integrating Moderna's mRNA technology with Carisma’s CAR macrophage platform. This partnership is expected to enhance the development and commercial potential of Carisma’s therapies, combining innovative approaches to accelerate the advancement of new cancer treatments.
Founded in 2016 and headquartered in Philadelphia, Pennsylvania, Carisma Therapeutics was originally known as CARMA Therapeutics Inc. and rebranded in May 2017. The company continues to advance its research and development programs, striving to bring transformative therapeutic solutions to patients with solid tumors and other serious diseases.
|
